MA51004A - Nouveaux analogues spirobicycliques - Google Patents

Nouveaux analogues spirobicycliques

Info

Publication number
MA51004A
MA51004A MA051004A MA51004A MA51004A MA 51004 A MA51004 A MA 51004A MA 051004 A MA051004 A MA 051004A MA 51004 A MA51004 A MA 51004A MA 51004 A MA51004 A MA 51004A
Authority
MA
Morocco
Prior art keywords
spirobicyclic
analogues
new
spirobicyclic analogues
new spirobicyclic
Prior art date
Application number
MA051004A
Other languages
English (en)
Inventor
Dirk Brehmer
Scott E Denmark
Lieven Meerpoel
Vineet Pande
Weimei Sun
Johannes Wilhelmus John F Thuring
Jonas Verhoeven
Guido Alfons F Verniest
Tongfei Wu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA51004A publication Critical patent/MA51004A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/40Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14Pyrrolo-pyrimidine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/167Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
MA051004A 2017-12-08 2018-12-06 Nouveaux analogues spirobicycliques MA51004A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762596441P 2017-12-08 2017-12-08
EP18163867 2018-03-26

Publications (1)

Publication Number Publication Date
MA51004A true MA51004A (fr) 2020-10-14

Family

ID=64664279

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051004A MA51004A (fr) 2017-12-08 2018-12-06 Nouveaux analogues spirobicycliques

Country Status (12)

Country Link
US (3) US11059850B2 (fr)
EP (1) EP3720865B1 (fr)
JP (1) JP7352544B2 (fr)
KR (1) KR20200097280A (fr)
CN (1) CN111479817B (fr)
AU (1) AU2018379456B2 (fr)
BR (1) BR112020010815A2 (fr)
CA (1) CA3084449A1 (fr)
IL (1) IL275129B2 (fr)
MA (1) MA51004A (fr)
MX (1) MX2020005944A (fr)
WO (1) WO2019110734A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202321249A (zh) 2015-08-26 2023-06-01 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
US11059850B2 (en) * 2017-12-08 2021-07-13 Janssen Pharmaceutica Nv Spirobicyclic analogues
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
CA3134779A1 (fr) * 2019-03-25 2020-10-01 California Institute Of Technology Inhibiteurs de prmt5 et leurs utilisations
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用prmt5抑制劑治療癌症之方法
CA3138349A1 (fr) * 2019-06-12 2020-12-17 Jonas VERHOEVEN Nouveaux intermediaires spirobicycliques
CA3166735A1 (fr) * 2020-01-07 2021-07-15 Pfizer Inc. Inhibiteur de prmt5 destine a etre utilise dans une methode de traitement du psoriasis et d'autres affections auto-immunes
CA3176912A1 (fr) 2020-07-31 2022-02-03 Tango Therapeutics, Inc. Derives de piperidine-1-yl-n-pyridine-3-yl-2-oxoacetamide utiles pour le traitement des cancers deficients en mtap et/ou a accumulation de mta

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4224438A (en) 1970-07-14 1980-09-23 Boehringer Mannheim Gmbh Adenosine-5'-carboxylic acid amides
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
EP0970342A1 (fr) * 1997-03-13 2000-01-12 Peter Spielberger Etui pour armes legeres
WO2003039523A2 (fr) 2001-11-05 2003-05-15 Exiqon A/S Oligonucleotides modifies a l'aide de nouveaux analogues d'arn-l-alpha
US7034147B2 (en) 2001-11-29 2006-04-25 Irm Llc Nucleoside analog libraries
CN1636009A (zh) 2002-02-19 2005-07-06 Cv医药有限公司 A1 腺苷受体的部分和全促效药
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
WO2005005450A1 (fr) 2003-07-15 2005-01-20 Mitsui Chemicals, Inc. Procede de synthese d'un bisdinucleoside cyclique
EP1694642A4 (fr) 2003-12-19 2010-10-06 Koronis Pharmaceuticals Inc Heterocycles mutagenes
EP1844062A2 (fr) 2005-01-21 2007-10-17 Methylgene, Inc. Inhibiteurs d'adn-methyltransferase
US20110159111A1 (en) 2006-06-29 2011-06-30 Astex Therapeutics Limited Pharmaceutical combinations
US20080132525A1 (en) 2006-12-04 2008-06-05 Methylgene Inc. Inhibitors of DNA Methyltransferase
US8962580B2 (en) 2008-09-23 2015-02-24 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
WO2011075665A2 (fr) 2009-12-18 2011-06-23 President And Fellows Of Harvard College Composés promouvant la réplication des cellules bêta et méthodes d'utilisation de ces composés
EP2646454B1 (fr) 2010-12-03 2015-07-08 Epizyme, Inc. Modulateurs à base de 7-déazapurine de l'histone méthyltransférase et procédés d'utilisation de ceux-ci
AU2011341441A1 (en) 2010-12-03 2013-06-20 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
CN103354808B (zh) 2010-12-16 2016-08-10 Abbvie公司 抗病毒化合物
EP2694524B1 (fr) 2011-04-04 2016-05-18 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Dérivés de 2'-o-aminooxyméthyl nucléoside pour l'utilisation dans la synthèse et la modification de nucléosides, nucléotides et oligonucléotides
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
WO2014035140A2 (fr) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Composés et compositions pour la modulation de l'activité histone méthyltransférase
US20140100184A1 (en) 2012-08-31 2014-04-10 Baylor College Of Medicine Selective inhibitors of histone methyltransferase dot1l
EP2935241A1 (fr) 2012-12-21 2015-10-28 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
US9745291B2 (en) 2012-12-21 2017-08-29 Epizyme, Inc. PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
JP6678455B2 (ja) 2012-12-21 2020-04-08 エピザイム,インコーポレイティド Prmt5阻害剤およびその使用
US9908887B2 (en) 2012-12-21 2018-03-06 Epizyme, Inc. PRMT5 inhibitors and uses thereof
WO2014145214A2 (fr) 2013-03-15 2014-09-18 Ohio State Innovation Foundation Inhibiteurs de prmt5 et leurs procédés d'utilisation
EP3091984B1 (fr) 2014-01-09 2020-04-22 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Benzoxazine substituée et composés associés
US20170198006A1 (en) 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
DK3164130T3 (da) 2014-07-01 2019-10-28 Millennium Pharm Inc Heteroaryle forbindelser anvendelige som inhibatorer af sumo-aktiverende enzym
CN107278205A (zh) 2015-02-24 2017-10-20 辉瑞大药厂 用作抗癌药的取代的核苷衍生物
TW202321249A (zh) * 2015-08-26 2023-06-01 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
CN108884108B (zh) 2016-03-10 2021-08-31 詹森药业有限公司 用于用作prmt5抑制剂的取代核苷类似物
WO2018065365A1 (fr) 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5
PE20190706A1 (es) 2016-10-03 2019-05-17 Janssen Pharmaceutica Nv Analogos novedosos de carbanucleosidos sustituidos de sistema anular monociclico y bicicilo para su uso como inhibidores de prmt5
MA47594A (fr) 2017-02-27 2020-01-01 Janssen Pharmaceutica Nv Utilisation de biomarqueurs dans l'identification de patients atteints d'un cancer sensibles à un traitement avec un inhibiteur de prmt5
US11059850B2 (en) * 2017-12-08 2021-07-13 Janssen Pharmaceutica Nv Spirobicyclic analogues

Also Published As

Publication number Publication date
IL275129B1 (en) 2023-06-01
BR112020010815A2 (pt) 2020-11-10
EP3720865B1 (fr) 2024-03-13
AU2018379456B2 (en) 2022-11-24
KR20200097280A (ko) 2020-08-18
RU2020122212A (ru) 2022-01-10
US20230303612A1 (en) 2023-09-28
JP7352544B2 (ja) 2023-09-28
MX2020005944A (es) 2020-08-24
EP3720865C0 (fr) 2024-03-13
US20200369707A1 (en) 2020-11-26
CN111479817A (zh) 2020-07-31
JP2021505582A (ja) 2021-02-18
RU2020122212A3 (fr) 2022-01-10
IL275129A (en) 2020-07-30
CA3084449A1 (fr) 2019-06-13
CN111479817B (zh) 2023-03-21
US20210380627A1 (en) 2021-12-09
EP3720865A1 (fr) 2020-10-14
WO2019110734A1 (fr) 2019-06-13
US11059850B2 (en) 2021-07-13
IL275129B2 (en) 2023-10-01
US11702441B2 (en) 2023-07-18
AU2018379456A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
DK3731771T3 (da) V462033dk00
DE202018003363U8 (de) Handgelenkssphygmomanometer
MA51004A (fr) Nouveaux analogues spirobicycliques
CL2018000524S1 (es) Golilla
DK3351526T3 (da) Diisopentylterephthalat
MA45430A (fr) Analogues de célastrol
DK3568655T3 (da) Rekuperator
DK3571580T3 (da) Load-logical-and-shift-guarded-instruktion
DK3445742T3 (da) Krystallin tapentadolphosphat
DK3612237T3 (da) Genterapi
DK3568506T3 (da) Offeranode
DK3576686T3 (da) Brokbind
DK3676276T3 (da) Spirothietannukleosider
DK3576718T3 (da) Pastil
FI11704U1 (fi) Liittopuujärjestely
DK3510051T3 (da) Carboxylalkylchitosan
DK3642136T3 (da) Veksellad
DK3395159T3 (da) Ballepresse
ES1205411Y (es) Maleta-Gaveta
ES1198359Y (es) Columbario
FI11529U1 (fi) Ontelolaatan kannake
ES1145433Y (es) Jamonero multiposicionable
DK3645955T3 (da) Buffertank
MA47846A (fr) Nouveaux polyimino-cétoaldéhydes
DK3401461T3 (da) Falsetagtegl